Evidence map›Paper›PMID 39129018›Full record

Trial reportMalaria journal2024

Community acceptance of a novel malaria intervention, Attractive Targeted Sugar Baits, in the Zambia phase III trial.

Erica Orange, Annie Arnzen, Chuma Muluma, Situmbeko Akalalambili, Titus Tobolo, Frank Ndalama, Chama Chishya, Kochelani Saili, Ruth A Ashton, Thomas P Eisele and 10 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
In one paragraph

Trial report in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Erica OrangePATH, Seattle, WA, USA. eorange@path.org.
Annie ArnzenPATH, Seattle, WA, USA. aarnzen@path.org.
Chuma MulumaPATH, Kaoma, Zambia.
Situmbeko AkalalambiliPATH, Kaoma, Zambia.
Titus ToboloPATH, Kaoma, Zambia.
Frank NdalamaPATH, Kaoma, Zambia.
Chama ChishyaPATH, Kaoma, Zambia.
Kochelani SailiPATH, Kaoma, Zambia.
Ruth A AshtonCentre for Applied Malaria Research and Evaluation, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Thomas P EiseleCentre for Applied Malaria Research and Evaluation, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Joshua YukichCentre for Applied Malaria Research and Evaluation, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Irene KyomuhangiCentre for Applied Malaria Research and Evaluation, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.
John MillerPATH, Lusaka, Zambia.
Kafula SilumbePATH, Lusaka, Zambia.
Javan ChandaPATH, Lusaka, Zambia.
Busiku HamainzaNational Malaria Elimination Centre, Lusaka, Zambia.
Joseph WagmanPATH, Washington DC, WA, USA.
Laurence SlutskerIndependent Consultant, Atlanta, GA, USA.
Thomas R BurkotAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.
Megan LittrellPATH, Washington DC, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommunity acceptance is an important criterion to assess in community trials, particularly for new tools that require high coverage and use by a target population. Installed on exterior walls of household structures, the attractive targeted sugar bait (ATSB) is a new vector control tool designed to attract and kill mosquitoes. ATSBs were evaluated in Western Zambia during a two-year cluster randomized controlled trial to assess the efficacy of ATSBs in reducing malaria transmission. Community acceptance of ATSBs was critical for successful trial implementation.

methodsA community engagement strategy outlined activities and key messages to promote acceptance. Annual cross-sectional surveys, conducted during the peak transmission period, assessed households for presence of ATSBs as well as perceived benefits, concerns, and willingness to use ATSBs. Sixteen focus group discussions and 16 in-depth interviews, conducted at the end of each ATSB station deployment period, obtained a range of perceptions and household experiences with ATSB stations, as well as ITN use in the context of ATSB deployment.

resultsMethods used during the study to promote acceptance and continued use of ATSBs were effective in achieving greater than 90% coverage, a high (greater than 70%) level of perceived benefits, and fewer than 10% of households reporting safety concerns. Common facilitators of acceptance included the desire for protection against malaria and reduction of mosquitoes, trust in health initiatives, and understanding of the product. Common barriers to acceptance included misconceptions of product impact on mosquitoes, continued cases of malaria, association with satanism, and damage to household structures. DISCUSSION: Future use of the ATSB intervention will likely require activities that foster community acceptance before, during, and after the intervention is introduced. Additional research may be needed to understand the impact of different levels of community engagement on ATSB station coverage, ATSB station perception, and ITN use.

conclusionThere was high acceptance of ATSB stations during the trial in Western Zambia. Continuous and intense community engagement efforts contributed to sustained ATSB coverage and trust in the product. Acceptance of ATSBs during programmatic delivery requires further research.

Indexed as

MalariaMosquito ControlAdolescentAdultAnimalsCross-Sectional StudiesFemaleHumansInsecticidesMaleMiddle AgedSugarsYoung AdultZambiaInsecticidesSugarsAttractive targeted sugar baitCommunity acceptanceMalaria

Identifiers

PMID39129018
PMCPMC11318112

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.